TICKERNERD
Menu
RVMDRVMDHealthcare · Biotechnology

RVMD Stock Forecast: Revolution Medicines, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$204
+0.85% on the day

The 22 Wall Street analysts covering Revolution Medicines, Inc. hold a median 12-month price target of $225 — +10.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 15 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$43.7B
Ticker Nerd rank
35 / 100
Median analyst target
$225
Analysts covering
22
Total return, dividends reinvested
1W
−0.7%
1M
+10.1%
YTD
+155.8%
1Y
+465.5%
From 52W high
−1.6%
From 52W low
+471.1%
$36
$207
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RVMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Revolution Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
35 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
99
Value
90
Accruals
58
Volatility
53
Quality
45
Revisions
36
Growth
27
Issuance
9
Size
6

Momentum (99): The shares have been drifting up relative to others.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

Size (6): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RVMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RVMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200$250$300Oct 25Jan 26Apr 26Jul 26RVMDHigh $291Median $225Low $151

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says22 analysts
21 Buy1 Hold0 Sell
Low $151Median $225High $291

The green dot is the last close — the median target sits +10.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
11 Aug 2026Truist SecuritiesMaintainsBuy$210 → $231
6 Aug 2026Evercore ISI GroupMaintainsOutperform$220 → $230
6 Aug 2026GuggenheimMaintainsBuy$235 → $240
6 Aug 2026NeedhamMaintainsBuy$236 → $240
6 Aug 2026RBC CapitalMaintainsOutperform$182 → $203
6 Aug 2026WedbushMaintainsOutperform$192 → $201
23 July 2026WedbushMaintainsOutperform—
23 July 2026WedbushMaintainsOutperform$181 → $192
20 July 2026NeedhamMaintainsBuy$235 → $236
20 July 2026NeedhamMaintainsBuy—
9 July 2026GuggenheimMaintainsBuy$205 → $235
9 July 2026GuggenheimMaintainsBuy—
6 July 2026HC Wainwright & Co.ReiteratesBuy$195
6 July 2026HC Wainwright & Co.ReiteratesBuy—
6 July 2026MizuhoMaintainsOutperform$185 → $215
6 July 2026MizuhoMaintainsOutperform—
2 July 2026WedbushMaintainsOutperform$165 → $181
2 July 2026WedbushMaintainsOutperform—
30 June 2026Truist SecuritiesMaintainsBuy—
29 June 2026NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RVMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

RVMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
3
Fundamentals

Revolution Medicines, Inc. (RVMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−34.2×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
27.2×

Cheaper than 4% of US stocks

EV / EBITDA
−25.1×

Cheaper than 90% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−79.1%

Higher than 16% of US stocks

Return on assets
−30.1%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

RVMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RVMDRevolution Medicines, Inc.$43.7B
35
RPRXRoyalty Pharma plc$33.7B
86
ALNYAlnylam Pharmaceuticals, Inc.$30.2B
54
INSMInsmed, Inc.$27.0B
84
ROIVRoivant Sciences Ltd.$25.9B
36
MRNAModerna, Inc.$25.3B
75
INCYIncyte Corp.$24.0B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Revolution Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RVMD news & analysis

Why Revolution Medicines May Be Big Pharma's Next Takeover Target

24/7 Wall Street · 12 Aug 2026positive

The article discusses Revolution Medicines as a potential takeover target for large pharmaceutical companies. The pre-commercial oncology platform closed at $205.55 on August 11, 2026, giving it a market capitalization of $44.1 billion.

Why it matters — A Revolution Medicines watcher would care because reports of the company being a possible acquisition target for big pharma could affect how the company's platform and valuation are viewed.

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration

Business Wire · 10 Aug 2026neutral

BeOne Medicines and Revolution Medicines announced a multi-part collaboration that includes a clinical development partnership to evaluate drug combinations of select BeOne oncology assets with Revolution Medicines' targeted therapies for RAS-addicted cancers, as well as a regional commercialization arrangement.

Why it matters — RVMD watchers would care because the collaboration could expand the clinical evaluation and regional commercial reach of Revolution Medicines' targeted oncology pipeline.

High Risk, High Reward: Inside The Revolution Medicines Bull Case

Seeking Alpha · 7 Aug 2026positive

Revolution Medicines is presented as evolving from a clinical-stage biotech toward a near-term commercial oncology player, underpinned by its RAS(ON) inhibitor platform, a roughly $3.9 billion cash position, and additional committed capital. The piece highlights the potential FDA approval and commercial launch of daraxonrasib in pancreatic cancer as a key catalyst that could validate its broader RAS-targeted strategy.

Why it matters — RVMD watchers would care because the discussion focuses on the company's launch readiness, reduced near-term dilution risk, and the pivotal role daraxonrasib could play in transforming its financial profile.

RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View

Zacks Investment Research · 6 Aug 2026negative

Revolution Medicines reported a wider-than-anticipated loss for the second quarter and again raised its 2026 expense outlook. Investors are weighing the higher spending against the company's pipeline progress.

Why it matters — RVMD watchers would care because the raised expense guidance and larger loss signal rising cash burn that must be weighed against the company's clinical pipeline milestones.

Revolution Medicines Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026neutral

Revolution Medicines reported second-quarter 2026 results demonstrating continued investment in late-stage cancer programs, commercial launch preparations, and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies in pancreatic and lung cancer.

Why it matters — The update signals ongoing progress in the company's late-stage development and commercial readiness for its RAS-targeted oncology pipeline.

FAQ

Frequently asked questions about RVMD stock

What is the RVMD stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Revolution Medicines, Inc. have a median 12-month price target of $225, with estimates ranging from $151 to $291. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RVMD stock a buy right now?

Of the 22 analysts covering Revolution Medicines, Inc., 21 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Revolution Medicines, Inc. 35 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RVMD?

As at 15 Aug 2026, Revolution Medicines, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).

Will RVMD stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +10.5% from the last close, and Ticker Nerd's factor model ranks Revolution Medicines, Inc. 35 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RVMD stock forecast for 2030?

No analyst covering Revolution Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RVMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $151 to $291 over the next 12 months.

How has RVMD stock performed over the past year?

Revolution Medicines, Inc. returned +465.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Revolution Medicines, Inc. do?

Revolution Medicines Inc. is a clinical-stage precision oncology company focused on developing targeted cancer therapies.

What is the latest news on RVMD?

The most recent item we track (24/7 Wall Street, 12 Aug 2026): "Why Revolution Medicines May Be Big Pharma's Next Takeover Target". The article discusses Revolution Medicines as a potential takeover target for large pharmaceutical companies. The pre-commercial oncology platform closed at $205.55 on August 11, 2026, giving it a market capitalization of $44.1 billion.

Company

About Revolution Medicines, Inc.

Revolution Medicines Inc. is a clinical-stage precision oncology company focused on developing targeted cancer therapies. The company concentrates on inhibiting difficult-to-drug molecular targets within key cell growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways that are frequently altered in solid tumors. Its pipeline includes RMC-4630, a SHP2 inhibitor designed to disrupt signaling that supports tumor growth, as well as a portfolio of RAS(ON) inhibitors and programs targeting SOS1 and 4EBP1/mTORC1. These investigational therapies are being studied as both monotherapies and in combinations to address cancers driven by RAS and related pathway alterations. Revolution Medicines serves the biopharmaceutical and oncology treatment markets by discovering and advancing molecules intended for use in cancer care, typically in collaboration with healthcare providers and research centers. Founded in 2004 and headquartered in Redwood City, California, Revolution Medicines operates within the biotechnology sector, contributing to the development of next-generation targeted oncology drugs.

CEO Dr. Mark A. Goldsmith M.D., Ph.D. · 883 employees · United States · https://www.revmed.com